Ascelia Pharma
ISIN: SE0010573113 | Ticker: ACE | LEI: 5493002YR9VCJJPWYN08
Country: Sweden
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.
About Orviglance (Mangoral)
Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function.
About Oncoral
Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.
2000
Served areaWorldwide
HeadquartersHyllie Boulevard 34, 21532 Malmö – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 255,374,000.00 | 333,493,000.00 | 218,569,000.00 |
| Noncurrent Assets | N/A | 59,050,000.00 | 58,882,000.00 | 57,700,000.00 |
| Property Plant And Equipment | N/A | 301,000.00 | 238,000.00 | 163,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 57,061,000.00 | 57,063,000.00 | 57,074,000.00 |
| Current Assets | N/A | 196,324,000.00 | 274,611,000.00 | 160,869,000.00 |
| Current Advances To Suppliers | N/A | 8,279,000.00 | 6,175,000.00 | 5,359,000.00 |
| Other Current Receivables | N/A | 857,000.00 | 1,165,000.00 | 1,745,000.00 |
| Current Tax Assets Current | N/A | 1,748,000.00 | 4,395,000.00 | 2,785,000.00 |
| Cash and cash equivalents | 108,516,000.00 | 184,686,000.00 | 261,599,000.00 | 149,555,000.00 |
| Equity And Liabilities | N/A | 255,374,000.00 | 333,493,000.00 | 218,569,000.00 |
| Equity | 237,062,000.00 | 236,056,000.00 | 307,834,000.00 | 180,859,000.00 |
| Issued Capital | N/A | 28,697,000.00 | 34,576,000.00 | 34,871,000.00 |
| Retained Earnings | N/A | -286,491,000.00 | -405,827,000.00 | -533,478,000.00 |
| Additional Paidin Capital | N/A | 493,731,000.00 | 678,831,000.00 | 678,747,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 236,056,000.00 | 307,834,000.00 | 180,859,000.00 |
| Liabilities | N/A | 19,318,000.00 | 25,659,000.00 | 37,711,000.00 |
| Noncurrent Liabilities | N/A | 956,000.00 | 553,000.00 | 193,000.00 |
| Current Liabilities | N/A | 18,362,000.00 | 25,106,000.00 | 37,518,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 3,884,000.00 | 6,147,000.00 | 15,881,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 16,343,000.00 | 19,657,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 5,000.00 | 0.00 |
| Other Current Liabilities | N/A | 672,000.00 | 1,509,000.00 | 1,688,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Other Income | 756,000.00 | 317,000.00 | 827,000.00 |
| Profit Loss From Operating Activities | -93,428,000.00 | -137,948,000.00 | -147,007,000.00 |
| Finance Income | 11,800,000.00 | 10,439,000.00 | 17,816,000.00 |
| Finance Costs | 18,119,000.00 | 2,014,000.00 | 3,965,000.00 |
| Profit Loss Before Tax | -99,747,000.00 | -129,523,000.00 | -133,155,000.00 |
| Income Tax Expense Continuing Operations | -1,050,000.00 | -3,620,000.00 | -1,933,000.00 |
| Profit (loss) | -98,697,000.00 | -125,903,000.00 | -131,223,000.00 |
| Profit Loss Attributable To Owners Of Parent | -98,697,000.00 | -125,903,000.00 | -131,223,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -98,697,000.00 | -125,903,000.00 | -131,223,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -1,220,000.00 | 2,258,000.00 | 9,722,000.00 |
| Adjustments For Sharebased Payments | N/A | 7,873,000.00 | 5,919,000.00 | 1,627,000.00 |
| Other Adjustments For Noncash Items | N/A | 870,000.00 | 1,045,000.00 | 1,091,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 87,000.00 | 77,000.00 | 48,000.00 |
| Interest Received Classified As Operating Activities | N/A | 27,000.00 | 10,000.00 | 635,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 89,000.00 | -1,020,000.00 | -3,772,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -85,527,000.00 | -116,559,000.00 | -125,263,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 397,000.00 | 38,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | 75,991,000.00 | -38,000.00 | -65,000.00 |
| Proceeds From Issuing Shares | N/A | 98,653,000.00 | 200,000,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 643,000.00 | 944,000.00 | 1,016,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 92,725,000.00 | 184,871,000.00 | -1,100,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 83,189,000.00 | 68,274,000.00 | -126,428,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -7,019,000.00 | 8,639,000.00 | 14,384,000.00 |
| Cash and cash equivalents | 108,516,000.00 | 184,686,000.00 | 261,599,000.00 | 149,555,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 06.10.23 | Carin Linde | Other | Buy | SEK 9,486.80 |
| 06.10.23 | Carin Linde | Other | Buy | SEK 513.00 |
| 19.09.23 | Julie Brogren | Other | Buy | SEK 41,246.00 |
| 13.07.23 | Julie Brogren | Other | Buy | SEK 3,316.80 |
| 03.03.23 | Carin Linde | Other | Other | SEK 0.00 |
| 02.03.23 | Magnus Olafsson Corfitzen | Other | Other | SEK 0.00 |
| 20.02.23 | Niels Mengel | Other | Buy | SEK 74,350.20 |
| 20.02.23 | Niels Mengel | Other | Buy | SEK 72,432.08 |
| 17.02.23 | Niels Mengel | Other | Buy | SEK 50,940.00 |
| 17.02.23 | Niels Mengel | Other | Buy | SEK 49,680.00 |
SE0010573113
LEI5493002YR9VCJJPWYN08
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.